New drug combo aims to make bone marrow transplants safer
NCT ID NCT04395222
First seen Jan 08, 2026 · Last updated Jun 19, 2026 · Updated 25 times
Summary
This phase 2 trial tests whether adding the drug tocilizumab to a standard transplant regimen can prevent graft failure and graft-versus-host disease in people with blood cancers receiving a special type of bone marrow transplant. The study involves 21 participants and aims to replace a stronger immune-suppressing drug to improve recovery and reduce relapse. Results will be tracked for up to 5 years.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Weill Cornell Medical College
New York, New York, 10065, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
tocilizumab (also called Actemra)
What this could lead to
If successful, this could make haplo-cord transplants safer and more effective for people with blood cancers, reducing complications like graft failure and graft-versus-host disease.
What could go wrong
This is a small, early-phase trial with only 21 participants, so results may not apply broadly. The drug may not prevent graft failure or GVHD as hoped, and there are risks from the transplant itself.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.